Adocia is a biotechnology company which focuses on producing treatments for diabetes. It was founded in 2005, and headquartered in Lyon, France. The Company develops a BioChaperone Platform used for therapeutic protein delivery in regenerative medicine and chronic disease areas. There pipeline of products include: Biochaperone Lispro, Biochaperone Combo, Hinsbet, Biochaperone Human Glucagon, Biochaperone Glargine GLP-1, Biochaperone Prandial combinations for T1D.